Biodesixincis A Life Sciences Diagnostics Company Based In Louisvillecoloradofounded In 2005It Focuses On Innovative Diagnostic Tests And Development Servicesparticularly In The Fields Of Lung Disease And Oncologythe Company Went Public In October 2020 And Aims To Enhance Patient Care Through Personalized Diagnosticsintegrating Multi Omic Testing With Artificial Intelligence Biodesix Offers A Variety Of Diagnostic Testsincluding The Nodify Lung Nodule Risk Assessment Testswhich Help Assess The Risk Of Malignancy In Lung Nodulestheir Igr Portfolio Includes Tests Like Genestrat Ddpcr And Genestrat Ngsproviding Genomic Data To Guide Therapy Selection For Advanced Lung Cancer Patientsadditionallybiodesix Supports Biopharmaceutical Companies With Services Such As Translational Researchclinical Trial Supportand Regulatory Assistancethe Company Is Led By Ceo Scott Hutton And Employs Around 273 Peopleshowing Significant Growth In Its Diagnostic Services
